PET/CT在前列腺癌外照射放疗计划制定中的应用价值
综述讨论PET/CT在前列腺癌根治性放疗与挽救性放疗计划制定中的作用。现行一线影像对初诊分期和生化复发检测敏感性有限;多种PET示踪剂中PSMA配体似最敏感特异但尚未获美国FDA新药申请批准。回顾性和前瞻性研究提示PET/CT对前列腺放疗计划可能有重大影响,尚需前瞻性随机试验验证。
要点
- 现行一线影像对前列腺癌初诊分期和生化复发检测敏感性有限。
- PSMA配体似为最敏感特异的PET示踪剂,但尚未获美国FDA新药申请批准。
- 回顾性和前瞻性研究提示PET/CT对前列腺放疗计划可能有重大影响。
核心结论
- 回顾性和前瞻性研究提示PET/CT对前列腺放疗计划可能有重大影响。
- PSMA配体似为最敏感和特异的PET示踪剂,但尚未获美国FDA新药申请批准用于美国。
- 作者认为需要开展评估PSMA PET/CT对前列腺放疗计划临床影响的前瞻性试验。
研究设计与样本
- 综述,未报告系统检索范围。
- 评估的PET示踪剂包括18F-氟化钠、11C-乙酸、11C-或18F-胆碱、18F-氟昔洛韦及68Ga-或18F标记的PSMA配体。
主要发现
- 18F-FDG PET/CT已常规用于多种癌症的放疗计划,但对前列腺癌敏感性低。
- PSMA配体似为最敏感和特异的示踪剂,但尚未获美国FDA新药申请批准。
- 回顾性和前瞻性研究提示PET/CT对前列腺放疗计划可能有重大影响。
- 评估挽救性放疗计划中加入18F-氟昔洛韦PET/CT并设临床终点的前瞻性临床试验正在进行中。
关键数值与推荐
- 现行一线影像对前列腺癌初诊分期和生化复发检测疾病的敏感性有限。
- 18F-FDG PET/CT对前列腺癌敏感性低。
- PSMA配体似为最敏感和特异的示踪剂。
临床怎么用
- 根治性前列腺切除术后前列腺特异性抗原升高提示前列腺癌复发,此类患者仍可能通过挽救性放疗治愈。
- 为最大化治愈机会,照射体积应完全覆盖疾病范围,因此准确估计疾病位置对根治性和挽救性放疗计划均关键。
- 将PET整合入前列腺癌患者常规评估可能改善分期准确性和放疗计划。
局限性
- PSMA配体尚未获美国FDA新药申请批准用于美国。
- 作者认为需要开展评估PSMA PET/CT对前列腺放疗计划临床影响的前瞻性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiotherapy and radical prostatectomy are the definitive treatment options for patients with localized prostate cancer. A rising level of prostate-specific antigen after radical prostatectomy indicates prostate cancer recurrence, and these patients may still be cured with salvage radiotherapy. To maximize chance for cure, the irradiated volumes should completely encompass the extent of disease. Therefore, accurate estimation of the location of disease is critical for radiotherapy planning in both the definitive and the salvage settings. Current first-line imaging for prostate cancer has limited sensitivity for detection of disease both at initial staging and at biochemical recurrence. Integration of PET into routine evaluation of prostate cancer patients may improve both staging accuracy and radiotherapy planning. 18F-FDG PET/CT is now routinely used in radiation planning for several cancer types. However, 18F-FDG PET/CT has low sensitivity for prostate cancer. Additional PET probes evaluated in prostate cancer include 18F-sodium fluoride, 11C-acetate, 11C- or 18F-choline, 18F-fluciclovine, and 68Ga- or 18F-labeled ligands that bind prostate-specific membrane antigen (PSMA). PSMA ligands appear to be the most sensitive and specific but have not yet received Food and Drug Administration New Drug Application approval for use in the United States. Retrospective and prospective investigations suggest a potential major impact of PET/CT on prostate radiation treatment planning. Prospective trials randomizing patients to routine radiotherapy planning versus PET/CT-aided planning may show meaningful clinical outcomes. Prospective clinical trials evaluating the addition of 18F-fluciclovine PET/CT for planning of salvage radiotherapy with clinical endpoints are under way. Prospective trials evaluating the clinical impact of PSMA PET/CT on prostate radiation planning are indicated.
引用
- Calais J, Cao M, Nickols NG, et al. The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. J Nucl Med. 2018. PMID: 29301928. doi:10.2967/jnumed.117.196444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。